Science News
from research organizations

Novel Anti-tumor Vaccine Developed

Date:
October 3, 2008
Source:
Children's National Medical Center
Summary:
A novel anti-tumor vaccine for neuroblastoma and melanoma is showing significant impact on tumor growth in mice, according to new research published in Cancer Immunology, Immunotherapy. The vaccine uses the tumor's own protein to induce an immune system response, allowing for a personalized approach to treatment.
Share:
       
FULL STORY

A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice, according to new research published in the October edition of the research journal Cancer Immunology, Immunotherapy.

The vaccine uses the tumor's own protein to induce an immune system response, allowing for a personalized approach to treatment.

The vaccine and delivery system, developed in the laboratory of Children's National Chief of General and Thoracic Surgery Anthony Sandler, MD, involves the creation of synthetic microparticles known as "immune stimulatory antigen loaded particles" (ISAPs), that consist of tumor antigens (proteins) from the specific tumor to be targeted, as well as immune stimulatory agents. The ISAPs are detected and engulfed by specialized immune cells and sensed to be immune-stimulating "foreign bodies."

The study shows that ISAPs are effective at blocking the growth of tumors in mice by inducing activation of immune cells that then stimulate the immune system to specifically target the tumor whose antigens match those that are loaded in the particles – known as tumor specific immunity.

The research team also discovered, however, that the impact of ISAPs on tumor growth was partially mitigated by an increased presence of regulatory t-cells (T-reg) when ISAPs are introduced into the body. The researchers believe that T-regs play a key role in how the vaccine impacts tumor growth by suppressing the development of the specific immune cells needed to combat the tumor. By adding a T-reg suppressor such as cyclosphosphamide or anti-CD25 antibody, the scientists were able to have a greater impact on preventing tumor growth using the ISAP approach.

"For tumors like neuroblastoma, reduction to minimal residual disease with standard therapies like chemotherapy and/or surgical resection and subsequent treatment with this vaccine could quite possibly cure the patient of the disease in the not too distant future," said Dr. Sandler, lead author of the study. "Creation of ISAPs allows us to target our treatments to the specific tumor of interest, a capability that will more effectively combat a wide range of these tumors in a personalized fashion."

The study was funded by the National Institutes of Health and the American Cancer Society.


Story Source:

The above post is reprinted from materials provided by Children's National Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Children's National Medical Center. "Novel Anti-tumor Vaccine Developed." ScienceDaily. ScienceDaily, 3 October 2008. <www.sciencedaily.com/releases/2008/10/081002172249.htm>.
Children's National Medical Center. (2008, October 3). Novel Anti-tumor Vaccine Developed. ScienceDaily. Retrieved July 31, 2015 from www.sciencedaily.com/releases/2008/10/081002172249.htm
Children's National Medical Center. "Novel Anti-tumor Vaccine Developed." ScienceDaily. www.sciencedaily.com/releases/2008/10/081002172249.htm (accessed July 31, 2015).

Share This Page: